Pricing Log in Create free account
Friday 6 November 2026 Export NEUP’s income statement to Excel — free account

Neuphoria Therapeutics Inc.

NEUP Healthcare Biotechnology

Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025.

Revenue
−107.3%
EPS
+83.6%
Free cash flow
+133.9%

Quarter to June 2026, against a year earlier

2.80 0.03 +1.08%
Market cap
$15.0M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
n/a
Altman Z
−7.55
Beneish M
831.96
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 14.99
Revenue ttm 15.66
Net income ttm (13.45)
Free cash flow ttm (12.35)
Net debt Q (19.87)
Valuation
P/E 0.00
Forward P/E (1.85) (negative: loss-making)
Price / sales 0.79
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.50
Financial health
Current ratio Q 27.85 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 0.00
Growth
Revenue growth Q −107.32% (below 0%: shrinking)
Operating income growth Q −14.83% (below 0%: shrinking)
EPS, this year +40.29% (at or above 15%: strong)
EPS, next year A −1.23% (below 0%: weak)
Revenue, next year A +788.06% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A −13.71% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.4×, against a ten-year median of 1.2×; over the ten years it ranged from −14.1× in 2024 to 1,672× in 2022.
P/S against its own 10 years 10.59%
10-year low 10-year high
P/B against its own 10 years 23.61%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 12 13 14 20
Receivables 0 0 0 1
Inventory — — — —
Other — — — —
13 13 15 21
2023 2024 2025 2026
Payables 1 2 1 0
ST’ Debt — — — —
Other — — — —
3 4 4 1

Compound Annual Growth %

10y 5y 3y
Sales — 19.07% 83.09%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (7.11%) 3.78%

Earnings Trends EPS, adjusted, against the consensus

Q4 FY26 Estimate −0.56 Actual −0.13

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.56 −5.79 Miss by 5.23
Q2 FY25 −0.56 −0.77 Miss by 0.21
Q3 FY26 −0.56 −0.09 Beat by 0.47
Q4 FY26 −0.56 −0.13 Beat by 0.43

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 (4.41) (0.77) (0.09) (0.95) (3.06)
’25 (0.62) (1.23) 6.55 (5.79) (0.23)
’24 (7.90) — (2.83) (3.37) (18.61)
’23 — (0.01) — — (29.05)
’22 — (0.01) — (0.01) (25.20)
’21 — 0.00 — (0.01) (18.00)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — 1
’25 15 0 — 1 16
’23 — 0 — — 0
’22 — 0 — 0 0
’20 — 0 — 0 0
’19 — 1 — — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (4) (6) (3) 1 (12)
’25 (4) (3) 11 (4) 0
’24 (4) (5) (2) (3) (15)
’23 — (6) — (14) (15)
’22 — (9) — (16) (16)
’21 — (1) — (6) (6)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (4) (6) (3) 1 (12)
’25 (4) (3) 11 (4) 0
’24 (4) (5) (2) (3) (15)
’23 — (6) — (14) (15)
’22 — (9) — (16) (16)
’21 — (1) — (6) (6)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 14 3 0 0 — 0 0 — 16 1 (24.2%) 10 — — +788.1%
Gross margin, % 0.00 0.00 0.00 0.00 0.00 100.00 100.00 — 100.00 100.00 +100.0 pt
EBT (10) (24) (12) (6) (7) (16) (22) (16) (1) (14) +3.4%
EBT margin, % (71.15) (874.26) (2,428.24) (19,212.42) 0.00 (8,324.93) (145,411.49) 0.00 (5.35) (1,157.48) (1,086.3) pt
Net income 0 (19) (7) (4) (6) (16) (21) (15) 0 (13) n/m
Per share, $
Per share, $ Revenue 61.63 12.45 2.03 0.13 0.00 0.31 0.02 0.00 9.64 0.27 (45.4%)
Earnings (22.55) (83.23) (30.02) (18.94) (18.00) (25.20) (29.05) (18.61) (0.23) (3.06) (19.9%)
Cash flow (0.80) (65.97) (44.33) (10.44) (15.61) (25.20) (21.54) (17.64) 0.05 (2.81) +15.0%
Capex 0.00 0.00 0.00 0.00 0.07 0.20 0.00 0.00 0.00 0.00 n/m
Free cash flow (0.80) (65.97) (44.33) (10.44) (15.54) (25.00) (21.54) (17.64) 0.05 (2.81) +15.0%
Book value 135.13 56.26 47.81 34.43 98.55 65.93 32.38 21.02 11.71 5.60 (29.8%)
Shares, m 0 0 0 0 0 1 1 1 2 4 +38.8%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 — 0.00 0.00 — 0.00 0.00 0.0
P/S 558.54 558.54 558.54 558.54 — 1,463.61 574.69 — 0.74 1.23 534.3
P/B 21.54 21.54 21.54 21.54 — 15.27 0.00 — 0.61 0.78 12.9
EV/Sales 543.25 543.25 543.25 543.25 — 1,408.25 543.36 — (0.12) 0.02 515.6
EV/FCF (80.32) (80.32) (80.32) (80.32) — (19.13) (4.49) — (8.12) (0.02) (44.1)
Cash, $m
Cash, $m Operating cash flow 0 (15) (11) (3) (6) (16) (15) (15) 0 (12) +59.6%
Capex 0 0 0 0 0 0 — — — — n/m
Free cash flow 0 (15) (11) (3) (6) (16) (15) (15) 0 (12) +59.6%
Balance, $m
Balance, $m Working capital 31 17 8 0 21 28 11 9 11 20 (4.7%)
Net debt (19) (3) 3 5 (21) (24) (12) (13) (14) (20) +0.4%
Shareholders’ equity 31 13 12 9 36 41 22 17 19 25 (2.6%)
Returns, %
Returns, % ROA (9.20) (77.11) (16.91) (15.63) (20.26) (35.91) (56.31) (55.12) (1.31) (46.95) (37.7) pt
ROIC 0.00 0.00 0.00 0.00 (24.03) (57.33) (138.68) (229.05) (14.97) (217.17) (217.2) pt
ROE (23.77) (85.08) (60.13) (47.24) (29.37) (41.08) (67.56) (78.44) (2.03) (61.70) (37.9) pt
People
People Employees — — — — 7 7 8 8 8 1 (32.2%)
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 1.96 1.17 n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2025 · fundamentals updated 26 Oct 2026

Neuphoria Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
VAXX Vaxxinity, Inc. $15.5M — (loss-making) — (loss-making) −100.23% (below 0%: shrinking) n/m +17.00% (above 0%: growing) 0.00% 0.00% Compare
ABOS Acumen Pharmaceuticals, Inc. $15.5M — (loss-making) — — n/m +12.58% (above 0%: growing) 0.00% 0.00% Compare
CTXR Citius Pharmaceuticals, Inc. $15.3M — (loss-making) — — n/m −60.50% (below 0%: shrinking) 67.07% (785.39%) Compare
PLUR Pluri Inc. $15.0M — (loss-making) — (loss-making) −15.83% (below 0%: shrinking) n/m +25.03% (above 0%: growing) 58.51% (1,655.52%) Compare
NEUP Neuphoria Therapeutics Inc. $15.0M — (loss-making) — (loss-making) −107.32% (below 0%: shrinking) n/m +133.86% (above 0%: growing) 100.00% 0.00%
MRKR MARKER THERAPEUTICS, INC. $14.9M — (loss-making) — (loss-making) −51.00% (below 0%: shrinking) n/m −97.84% (below 0%: shrinking) 209.68% 0.00% Compare
KYNB Kyntra Bio Inc $14.8M 0.1× — (loss-making) −209.35% (below 0%: shrinking) n/m −131.50% (below 0%: shrinking) 100.14% 1,192.27% Compare
ATYR aTyr Pharma, Inc. $14.8M — (loss-making) — (loss-making) −90.75% (below 0%: shrinking) n/m +32.22% (above 0%: growing) 100.00% 0.00% Compare
ADAPY Adaptimmune Therapeutics PLC $14.6M — (loss-making) — (loss-making) −89.33% (below 0%: shrinking) n/m −174.72% (below 0%: shrinking) 81.71% (221.45%) Compare
Median of peers $15.0M — — −90.04% — −23.96% 74.39% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 18 September 2026

Ownership

Directors and executive officers, together less than 1%
Lynx1 Capital Management LP 16.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Neuphoria Therapeutics Inc. (NEUP) Latest News

9 Oct

Impact 4 · · Proactive Investors

24 Sep

Impact 4 · · GlobeNewswire

23 Jul

Impact 5 ·
Impact 5 ·
Impact 5 · · Proactive Investors

1 Jul

Impact 4 · · Stocktwits

26 Jun

Impact 4 · · Proactive Investors

8 Dec

Impact 4 · · PR Newswire
Impact 4 ·

4 Dec

Impact 3 · · GlobeNewswireSimply Wall St.Medical Device NetworkMotley FoolZacksMT NewswiresGuruFocus.comMT Newswires

2 Dec

Impact 3 · · PR Newswire

1 Dec

Impact 3 · · GlobeNewswire

24 Nov

Impact 3 · · GlobeNewswire

11 Nov

Impact 4 · · GlobeNewswireMT NewswiresClinical Trials ArenaMT NewswiresSimply Wall St.GuruFocus.comSimply Wall St.GuruFocus.com

31 Oct

Impact 3 · · Simply Wall St.

27 Oct

Impact 3 · · GlobeNewswire

24 Oct

Impact 3 · · Associated Press Finance

22 Oct

Impact 4 · · clinicaltrialsarena.com

20 Oct

Impact 4 · · GlobeNewswire
Impact 3 · · MT NewswiresClinical Trials ArenaMT NewswiresClinical Trials ArenaMT NewswiresMT NewswiresMT Newswires

29 Sep

Impact 4 · · GlobeNewswire

4 Sep

Impact 4 ·

28 Aug

Impact 3 ·

27 May

Impact 3 ·

20 May

Impact 4 ·

15 Apr

Impact 4 ·

3 Mar

Impact 4 · · GlobeNewswire

12 Feb

Impact 4 · · GlobeNewswire

25 Dec

Impact 3 ·

24 Dec

Impact 4 ·
stockrow.com/NEUP · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com